Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Partial PPAR-gamma agonist PAM-1616 shows promise in models of diabetes and obesity

Feb. 4, 2011

Temple University divulges new leptin receptor agonists

Feb. 3, 2011

Zymenex's Lamazym advances to phase II in alpha-mannosidosis

Feb. 3, 2011

New GPR119 receptor agonists presented

Feb. 3, 2011

Prolia available in Quebec for postmenopausal osteoporosis

Feb. 3, 2011

New bombesin BB3 receptor agonist MK-5046 shows preclinical potential to treat obesity

Feb. 3, 2011

FDA requests additional trial of Contrave

Feb. 2, 2011

Lixisenatide demonstrates noninferiority to exenatide in phase III GetGoal-X trial

Feb. 2, 2011

BioMarin begins phase III trial of N-acetylgalactosamine 6-sulfatase in MPS IVA

Feb. 2, 2011

Phase IIb follow-up data show efficacy of KUR-111 in bone regeneration

Feb. 2, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...